The Endosleeve is built on more than ten years of international clinical research. A selection of foundational studies and scientific news from the field, accessible for readers who wish to go further.
The most recent publications validating the efficacy, safety and long-term durability of the Endosleeve technique. Available in international medical databases.
First analysis of ESG results with follow-up of up to 10 years: a maintained average weight loss of 15.8% of total weight, an excellent safety profile, no mortality. Confirms the durability of the technique. Jirapinyo & Thompson et al.
Joint guideline of the American (ASGE) and European (ESGE) digestive endoscopy societies, establishing ESG as the reference endoscopic bariatric therapy for adults living with obesity. Jirapinyo, Hadefi, Thompson et al.
Comparative study between semaglutide (a GLP-1 drug) and ESG: the Endosleeve offers a lasting alternative, without lifelong treatment, with an excellent efficacy/safety ratio. Haseeb, Jirapinyo, Thompson et al.
A landmark prospective, multicentre, randomised study — demonstrating the efficacy and safety of ESG compared with intensive nutritional management. Abu Dayyeh et al., 2022.
Analysis of the efficacy of combined therapy (anti-obesity drugs + ESG), with optimal timing and agents — weight loss of up to 24%. Jirapinyo, Jaroenlapnopparat, Thompson.
Description of the evolution of the ESG technique, from the first human cases to the current standardised technique. Kumar, Abu Dayyeh, Lopez-Nava et al.
Our breakdowns of the topics that matter: durability of results, digestive safety, and endoscopic solutions after bariatric surgery.
A study published in the American Journal of Gastroenterology analyses ESG results with 10-year follow-up for the first time: 15.8% maintained weight loss, an excellent safety profile, few touch-ups needed. Proof of a durable strategy against obesity.
Learn moreUnlike the surgical sleeve, the Endosleeve preserves the stomach's anatomy and does not cause a significant increase in reflux. A particularly attractive option for patients concerned about this issue.
Learn moreSeveral years after a gastric bypass, weight regain is possible. The TORe (Transoral Outlet Reduction) endoscopically corrects the dilatation of the anastomosis, without further surgery: 8 to 15% weight loss within the year.
Learn moreGLP-1 drugs require lifelong weekly injections, with weight regain on discontinuation. The Endosleeve offers a unique alternative: a single, non-surgical procedure with lasting results — with efficacy that can be enhanced by a combined approach.
Learn moreScientific studies set the framework — the initial consultation translates them into personalised answers for your profile.
Book an appointment